LSLyudmila F. Stovba

Lyudmila F. Stovba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lyudmila F. Stovba has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of approaches of the World Health Assembly to the retention or destruction of variola virus stocks

    by Gennady G. Onishchenko, Онищенко Геннадий Григорьевич, Lyudmila F. Stovba, Стовба Людмила Федоровна, Oleg V. Chukhralya, Чухраля Олег Васильевич, Dmitry I. Paveliev, Павельев Дмитрий Игоревич, Sergey V. Savenko, Савенко Сергей Вадимович, et al.

    After smallpox eradication was certified in 1980, the international community faced the question of the fate of the remaining collections of Variola virus (VARV). Debate over their destruction has continued for more than four decades. Objective. To conduct a historical-chronological analysis of World Health Organization (WHO) and World Health Assembly (WHA) documents in order to trace changes in the arguments and approaches concerning the retention and possible destruction of VARV stocks. Resolutions of the World Health Assembly, WHO documents, and materials from the WHO Advisory Committee on Variola Virus Research were analyzed as sources; historical-chronological and comparative methods were employed. After storage was centralized in two WHO collaborating centers, the proposed timelines for destruction were repeatedly reconsidered. In 1999, the WHA authorized temporary retention to allow further international research; in 2002, retention was continued subject to results-oriented and time-limited studies. During the 2010s, risks associated with advances in synthetic biology became more prominent in the discussion. In 2019, the WHA extended the research programme for a further five years. Conclusion. The history of this issue reflects not a linear progression toward a final decision to destroy the VARV, but rather a periodic review of retention timelines and research conditions. The WHO Advisory Committee plays a pivotal scientific advisory role in evaluating the necessity, direction, and outcomes of VARV research, and its expert findings inform deliberations regarding the future of the stocks. The current WHO approach is characterized by a combination of rigorous research oversight, biosafety requirements, and periodic reviews of the research program.

  • Open Access

    The Preparation of Chromatographically Purified Anti-Smallpox Immunoglobulin from Equine Blood Serum

    by S. A. Mel’NIkov, S. V. Borisevich, D. A. Kutaev, E. V. Rozhdestvensky, A. E. Babichev, A. L. Khmelev, N. K. Chernikova, S. A. Nimirskaya, E. E. Popadyuk, G. A. Anan’INa, et al.

    The aim of the work was to obtain chromatographically purified anti-smallpox immunoglobulin from equine blood serum and evaluate its properties. Materials and methods . The horse blood serum containing antibodies to the vaccine virus, L-IVP strain, was used. Сhromatographic purification of serum was carried out on Akta Avant preparative chromatograph (GE HealthCare, Sweden), molecular parameter control at the stages of immunoglobulin production was conducted on the LC-20ad HPLC system (Shimadzu, Japan). The biological properties of immunoglobulin were evaluated in rabbits, white mice, and guinea pigs. The level of specific virus neutralizing antibodies was determined in the neutralization reaction on the chorionallantoic membrane (CAМ) of 12-day chicken embryos. Results and discussion . The technology for obtaining chromatographically purified anti-smallpox immunoglobulin from equine blood serum has been developed. At the initial stage, the immune blood serum of horses was purified by filtration through glass fiber cassette-type filters from fibrin sediment, residual quantity of lipids and lipoproteins, and then the immunoglobulin fraction was precipitated with a saturated solution of ammonium sulfate. At the next stage, ammonium salts, low molecular weight fractions, residual quantity of albumins and euglobulins were removed using ion exchange chromatographic purification. At the final stage, dimers, polymers, and aggregates of immunoglobulins were eliminated using gel filtration. The experimental series of immunoglobulin prepared using the developed technology is characterized by a high degree of purification. The monomer content in the finished product is at least 99 %, and the specific activity by titer of specific neutralizing antibodies – at least 1:16000.

  • Two-component vector-based vaccine Ad26.ZEBOV, MVA-BN-Filo against Ebola fever: A review of clinical studies

    by L. F. Stovba, O. V. Chukhralya, D. I. Paveliev, M. I. Soldatenkova, D. P. Belozerov, A. A. Petrov, S. V. Borisevich

    INTRODUCTION. High reactogenicity of the existing Ebola vaccines necessitates the development of safer and more efficacious alternatives. A solution is to use new recombinant vectorbased vaccines, such as Ad26.ZEBOV (a recombinant vaccine based on non-replicating human Ad26 serotype with an inserted glycoprotein gene of Zaire ebolavirus strain) and MVA-BN-Filo (a recombinant vaccine based on modified vaccinia Ankara strain), currently undergoing clinical trials to confirm their efficacy and safety. AIM. This study aimed to systematize clinical trial data in order to assess efficacy, safety, and immunogenicity of the two-component recombinant Ad26.ZEBOV, MVA-BN-Filo vaccine used to prevent Ebola hemorrhagic fever in various population groups. DISCUSSION. Literary sources were analyzed in the PubMed, ScienceDirect, and eLIBRARY.RU databases over the period of 2009–2024. Phase I–III clinical trials confirmed that the twocomponent Ebola vaccination regimen (Ad26.ZEBOV, MVA-BN-Filo) provides a strong and sustained immune response. Seroconversion reached 87–95% three weeks after the first administration and up to 100% after revaccination, with immunity lasting for at least a year. Adverse events (local and systemic, mild to moderate severity) were observed in half of the participants; serious adverse events were not associated with vaccination and occurred in less than 1%. In pregnant women, the vaccination did not increase the risk of adverse outcomes while ensuring the transmission of antibodies to the fetuses. In children and adolescents, seroconversion exceeded 90%; revaccination significantly enhanced the immune response. In HIV-infected individuals, seroconversion reached 80–85%, which is comparable to the general population. Malaria or helminthiasis did not reduce the immunization effectiveness. Considering the above, the World Health Organization and the European Medicines Agency approved this vaccination schedule in 2020 in adults and children over one year of age, including those with concomitant infections. CONCLUSIONS. The two-component Ad26.ZEBOV, MVA-BN-Filo vaccine shows high immunogenicity and a good safety profile. The primary and booster vaccination schedule is effective in adults, children over one year of age, pregnant women, and individuals with concurrent infections, including HIV, malaria, and helminthiasis. The vaccine reduces the risk of Ebola transmission and can be used for a mass immunization strategy in endemic regions and during the disease outbreaks.

  • Open Access

    Preclinical valuation of immunogenicity and effectiveness of inactivated cultural vaccine experimental patterns against coronaviral infection COVID-19

    by N. K. Cherniкova, D. A. Kutaev, V. V. Rubtsov, I. V. Shatohina, N. V. Boyarskaya, E. V. Rozhdestvenskiy, S. A. Nimirskaya, A. L. Khmelev, G. V. Borisevich, S. L. Kirillova, et al.

    Relevance. Research on the development of new, more advanced vaccines against Covid-19, both based on modern technologies and traditional inactivated ones, remains relevant. In the "48 Central Research Institute" of the Ministry of Defense of the Russian Federation, together with the Yaroslavl Factory of ready-made Dosage Forms of JSC R-Pharm, a cultural (based on Vero (B) cell culture) inactivated with beta-propiolactone chromatographically purified vaccine against coronavirus infection Covid-19 was developed. The aim of the work is to evaluate the results of preclinical studies on its immunogenicity and protective effectiveness in animal experiments. Materials and methods. The immunogenicity and protective activity of experimental vaccine samples with adjuvants aluminum hydroxide and CpG 1018 were evaluated, including in comparison with Sputnik V, after double immunization of Syrian hamsters with an interval of 21 days with intranasal infection with the virulent SARS-CoV-2 virus at a dose of 105 Plaqueforming units/individual. In an experiment on monkeys, the effects of the vaccine on double immunization were evaluated: humoral (virus neutralizing antibodies titer) and cellular immunity indicators for 1 year. Results and discussion. The optimal dose of the vaccine was selected – 15 mcg of protein and the composition of the adjuvants included in it was determined: 500 mcg of aluminum hydroxide and 10 mcg of synthetic oligodeoxynucleotide CpG 1018. The inactivated sorbed vaccine against Covid-19 coronavirus infection, when administered twice with an interval of 21 days, induces the formation of viral neutralizing antibodies in 80-100% of Syrian hamsters at titers of 1:20 or more 21 days after the completion of the immunization cycle and is characterized by a lung protection index ≥ 3.2 lg on the 6th day after infection with 105Plaque-forming units of virulent virus (variant “Delta”). The inactivated sorbed vaccine is capable of generating a humoral immune response in rhesus monkeys to both the “Delta” variant and the “Omicron” variant of the SARS-CoV-2 virus. Virus neutralizing antibodies for both variants persists in 100% of vaccinated animals for 180 days after double immunization. By 42 days after the completion of vaccination, there is an increase in cytotoxic T lymphocytes and a decrease in total B lymphocytes. Conclusions. The inactivated sorbed purified vaccine against Covid-19 coronavirus infection, when administered twice, is immunogenic for Syrian hamsters and protects them from intranasal infection with 1•105 Plaqueforming units of virulent virus. The vaccine is capable of generating a specific humoral immune response to both the “Delta” variant and the “Omicron” variant of the SARS-CoV-2 virus. Virus neutralizing antibodies for both variants persists in 100 % of animals for 180 days after double immunization. The effect of immunization on cellular immunity is shown.

  • Open Access

    Оrthopoxviruses of New World: review of scientific literature

    by L. F. Stovba, O. V. Chukhralia, A. A. Petrov, С. А. Мельников, D. P. Belozerov, M. A. Filippova, V. A. Kovalchuk, S. V. Borisevich

    Relevance. 3 agents raccoonpox, skunkpox and volepox belonged to orthopoxviruses of the New World until 2015 years. In last ten-years period skunkpox virus using as vector for creation recombinant vaccines for animals. After 2015 years this group supplemented some more agent primary called virus Alaska, was isolated from ill man. After 2020 years 6 causes of illness by this virus, now named borealpox virus, was registries. Aim. Summary of available information on viruses endemic to the North American continent. Evaluations of еffectivity vaccines on the base virus raccoonpox in laboratory conditions and in Wild World. Monitoring of changes pathogencity virus borealpox by clinical symptoms at infected peoples. Materials. The work uses data from publications posted on the websites of international biomedical research search engines% PubMed, Web of Science, Embase, etc. Results and discussion. Raccoon, skunk and vole smallpox viruses endemic to North America, isolated from their host animals, have specific features that affect their distribution in nature. The high degree of genetic similarity between orthopoxvirus species suggests that rodents may represent the primary ecological reservoir for members of this genus. The most studied representative of the raccoon pox pathogen has an attenuated phenotype and is used as a vector for the creation of vaccine preparations. Based on the construction of a phylogenetic tree, it was found that the orthopoxviruses of the New World are closely related to the orthopoxviruses of the Old World (Eurasia and Africa), and the Alaska virus, capable of infecting humans, forms a separate monophyletic branch. Sequencing of the Alaska virus genome revealed that its closest relative is the Akhmet virus. Human infection with the boreal smallpox virus occurs through contact with small mammals. Conclusion. Analysis of the published data makes it possible to establish that raccoonpox, skunkpox and volepox viruses are not pathogenic to humans. Vaccines on the base virus raccoonpox is immunogenicity and safety for animals and can using as baits. Virus borealpox evoke variola-like disease, proceed in light form at immunedominante peoples. Infected of man by this virus origin by contacts with small mammalians. Study of genomic virus structures all 4 orthopoxviruses of New World allowed conducting their phylogenetic analysis. Established, that raccoonpox, skunkpox and volepox viruses form these parating branch relatively other orthopoxviruses species. Agent of borealpox form the fisting monophyletic branch with localization between orthopoxviruses Old World and New Word, but narrowly related with orthopoxviruses Old World and this relationship execute still on the level of their ancestors.

  • Use of the Highly Attenuated Vaccinia Virus, Strain NYVAC, as Recombinant Vector for Construction Vaccine Against HIV Infection

    by Lyudmila F. Stovba, Alexandr А. Petrov, Oleg V. Chukhralia, Dmitriy I. Paveliev, Sergey A. Melnikov, Sergey V. Borisevich

    Despite significant advances in antiretroviral therapy (ART), HIV/AIDS continues to pose a serious global public health threat. According to 2021 statistics, there were 1.5 million new HIV infections worldwide, with approximately 38.4 million people living with the virus. While ART has transformed HIV into a manageable chronic condition, a preventive vaccine remains the most promising solution for controlling the epidemic, particularly in developing countries with limited healthcare resources. This review focuses on the attenuated vaccinia virus strain NYVAC as a promising recombinant vector platform for HIV vaccine development. Therefore this recombinant vector was used as share in strategy immunization prime/boost in common with DNA-vaccines. As vector’s virus NYVAC is attenuated and safe for man with immunodeficiency as considerate for creation of vaccines, in main, against AIDS. Only in alone clinical trial RV144 was received modest positive response against challenge by human deficiency virus. Therefore, comparative characteristic of immune responses, inducing by recombinant vector ALVAC, used in this trial, with recombinant vector NYVAC with identical conditions, reveal preference vector NYVAC. It triggers research about substitution vector ALVAC on NYVAC, preserved regimen mimicking that of the RV144: two prime / two boost, using only one vector, insertion maximum quantity genes of antigenic determinants human immunodeficiency virus, addition protein gp120 for enhance quantity envelope proteins. Besides this, replication-restricted strain NYVAC has been modified by reincorporation in her genome of the earlier deleted genes K1L and C7L with generation vector’s virus NYVAC-C-KC, which replicate in human cells — keratinocytes and dermal fibroblasts. Again receiving strain NYVAC-C-KC, additionally modified by deleting immunomodulate gene B19R an inhibitor of the type I interferon response with generated new vector’s virus NYVAC-C-KC-∆ B19R, which expressed greater quantity antigenic determinants of human immunodeficiency virus by increasing time reproduction in human cells. All this properties of new vector’s virus NYVAC, most probably, positive plead on effectivity vaccine against HIV infection.

  • Open Access

    Anti-Vector Immune Response Formed after Immunization with Recombinant Vaccines Based on the Vaccinia Virus, MVA Strain

    by L. F. Stovba, N. K. Chernikova, A. L. Khmelev, S. V. Borisevich

    The search for safe approaches to primary immunization of the adult population under the absence of herd immunity to orthopoxviruses, when re-initiation of smallpox vaccination campaign is required, is currently very relevant. Thereat, the clinical trials of recombinant vaccines based on the vaccinia virus, MVA strain, against different illnesses confirm that they are safe for humans and in addition to target efficiency (capacity to induce immunity to proteins expressed by embedded foreign genes), show immunogenicity to vector – vaccinia virus. The aim of the review was to evaluate anti-vector immunity level in people immunized by recombinant viral vaccines, based on vaccinia virus, MVA strain. Explicit experimental data on the level of anti-vector immunity in response to immunization with recombinant vaccines in different countries of the world are presented. Those studies were mainly carried out with recombinants containing embedded immunodominant genes of human immunodeficiency virus (HIV), as the number of works on the creation of recombinant vaccines expressing the antigen determinants of HIV significantly exceeds the number of those on recombinant preparations based on vaccinia virus; the vaccines are successfully used in medical practice and are safe even for people with immunodeficiency conditions. The results obtained indicated an increase in anti-vector immunity with escalation of vaccine dose and peak indicators after two immunizations. Further injections of the vaccine did not lead to increase in the virus neutralizing antibodies, their production gradually decreased over a period of one year or more. In addition to the humoral immune response, cellular anti-vector immunity, represented mainly by CD8+ T-cells, was induced. The insertion of foreign genes did not affect the formation of anti-vector immunity, just as its level did not affect the development of humoral and cellular immune responses to proteins expressed by the embedded genes. Comparative characterization of the anti-vector immunity indices after immunization with recombinant vaccines and specific immunity in response to the IMVAMUNE® vaccine showed that their levels either corresponded to each other, or in the first case the values were even higher.

  • Open Access

    Rabbitpox

    by Lyudmila F. Stovba, Aleksandr A. Petrov, Dеnis P. Belozerov, Oleg V. Chukhralia, Sergey A. Melnikov, Sergey V. Borisevich

    Поскольку существует опасность реинтродукции вируса натуральной оспы (ВНО) из неизвестного резервуара или появления генетически подобного вируса с такими же патогенными свойствами, либо его синтетической копии, необходима адекватная лабораторная модель, наиболее полно имитирующая заболевание натуральной оспой и другими ортопоксвирусами человека. Вирус оспы кроликов способен вызывать у кроликов чрезвычайно тяжелое контагиозное заболевание с высокой летальностью, которое имитирует заболевание у человека натуральной оспой. За все время наблюдения не зафиксировано ни одного случая заболевания человека оспой кроликов. Цель работы – обобщение материалов по исследованию вируса оспы кроликов и анализ симптомов данного заболевания у кроликов, имитирующих заболевание натуральной оспой у человека, применительно к разработке новых противооспенных препаратов. Источниковая база исследования – англоязычная научная литература, доступная через сеть Интернет. Метод исследования – аналитический. Результаты и обсуждение. Оспа кроликов впервые зафиксирована в начале 1930-х гг. у лабораторных кроликов в г. Утрехте, Нидерланды, затем в США в Рокфеллеровском Институте в г. Нью-Йорке. Начиная с 1941 г. вспышки оспы кроликов периодически отмечались в исследовательских институтах США и Европы. Однако эпизоотий такой болезни среди зайцев в дикой природе в мире не зарегистрировано. Анализ литературы позволил выявить удачные примеры использования модели «кролик–вирус оспы кроликов» для доклинических исследований защитной эффективности противоортопоксвирусных вакцин, моноклональных антител, препаратов на основе мРНК и химиопрепаратов (тиосемикарбазон, цидофовир, тековиримат, бринцидофовир и др.) при различных способах инфицирования, включая ингаляционный. Также эта модель удобна для оценки диагностических наборов для обнаружения ортопоксвирусов. Заключение. Модель «кролик-вирус оспы кроликов» является безопасной для человека и перспективной для моделирования различных патологических состояний при проведении различных медико-биологических исследований ортпоксвирусных инфекций, оценки эффективности противооспенных иммунобиологических препаратов, химиопрепаратов и диагностических наборов.

  • Open Access

    Smallpox Vaccine LC16m8: Production, Properties, and Prospects

    by L. F. Stovba, O. V. Chukhralya, A. A. Petrov, S. A. Mel’nIkov, D. I. Pavel’eV, S. V. Borisevich

    Abrogation of obligatory vaccination against smallpox has lead to degradation of herd immunity and humanity has become vulnerable to long known infections, such as monkeypox (mpox), cowpox, camelpox, buffalopox and emerging ones, caused by viruses Alaska and Akhmeta. This situation demands availability of safe smallpox vaccines, the immunogenicity of which is comparable to vaccines used in the period of smallpox elimination. The aim of this review is to analyze the research of Japanese scientists on the production and investigation of properties of the smallpox vaccine LC16m8 and to assess further prospects for the use of the LC16m8 strain. The LC16m8 vaccine was obtained based on one of the Lister clones and has been licensed in Japan since 1975. Whole-genome sequencing revealed that its main difference from the genome of the original strain is a mutation in the B5R gene, which determines its safety for laboratory animals and humans. The immunogenicity of the vaccine based on this strain is comparable to the immunogenicity of the first generation vaccines: Lister, Dryvax, Ikeda. According to WHO recommendations, second generation vaccines ACAM 2000 and third generation vaccines based on the LC16m8 strain are reserve drugs. However, the established fact that the LC16m8 strain, when passaged in cell culture, spontaneously reverts to the original variant of the Lister strain led to genetic engineering work to delete the B5R gene to obtain the LC16m8Δ mutant, which is not capable of reversion. A vaccine based on the LC16m8Δ strain could technically be classified as a fourth generation drug, and taking into account the high immunogenicity and relative safety of this strain based on the results of preclinical studies, there is a real prospect of producing an advanced and effective reserve drug based on it. Thus, analysis of long-term data on the study of the LC16m8 vaccine indicates that this drug is superior to other analogues of the 1st, 2nd and 3rd generation in terms of effectiveness and safety. Further genetic engineering work with this strain, which made it possible to obtain a safe but immunogenic genovariant of the LC16m8Δ strain, is a clear example of a productive movement towards the development of safe and effective fourth generation vaccines.


  • Open Access

    Epidemiology of Horsepox. The New Aspects

    by L. F. Stovba, A. A. Petrov, С. А. Мельников, O. V. Chukhralia, N. K. Cherniкova, S. V. Borisevich

     In the last 10 years, scientists' interest in the horsepox pathogen has increased sharply due to the obtaining of its chimeric copy and the discussion of whether it was used to create early smallpox vaccines and the dangers of technologies that allow the restoration of extinct pathogens of dangerous infections.The aim of the work is to summarize the materials on modern studies of the horsepox virus.The source base of the study is English-language scientific literature available via the Internet.The research method is an analysis of scientific sources on horsepox from the general to the specific. We considered the area of distribution of the virus, its epidemiological danger, phylogenetic relationship, data on the sequencing of the horsepox virus genome and the likelihood of its use in the creation of the first vaccines, as well as obtaining its chimeric copy, on the basis of which a new smallpox vaccine was created – TNX-801.Results and discussion. The horsepox virus belongs to the poxvirus family, the orthopoxvirus genus. Classical horsepox has previously been reported only in Europe (France), Mongolia, and Kenya. The complete nucleotide sequence of the horsepox virus genome MNR-76 isolated in Mongolia has been determined. In addition to genes common to all orthopoxviruses, it includes intact genes specific only to this virus, the homologues of which are fragmented in the genome of other orthopoxviruses. Phylogenetic analysis of a number of orthopoxviruses was performed and a phylogenetic tree was constructed based on the conserved central region of the genome and some of the more variable terminal regions. The data obtained indicate that horsepox virus is most closely related to vaccinia virus and rabbitpox virus strains. Although horsepox is currently considered extinct, its pathogen may persist in unknown reservoirs. The data on the sequencing of the horsepox virus genome, strain MNR-76, suggest that horsepox virus could have served as the basis for the first smallpox vaccines. A chimeric copy of the horsepox virus was obtained using synthetic biology, which was used to create a new smallpox vaccine, TNX-801. On its basis, a recombinant vaccine against SARS-CoV-2 was constructed. The restoration of "extinct viruses" using synthetic biology methods has led to intense debates about the benefits and risks of such research.Conclusion. It cannot be ruled out that the use of modern genetic engineering technologies may lead not only to the development of effective vaccines, but also to the production of new orthopoxviruses pathogenic for humans and animals, or to the reintroduction of smallpox, which is especially dangerous in the context of the virtual absence of smallpox immunity in the population and international control over experiments in the synthetic biology of dangerous pathogens.